LORIA, Paola
 Distribuzione geografica
Continente #
NA - Nord America 18.128
EU - Europa 7.800
AS - Asia 5.070
SA - Sud America 584
AF - Africa 52
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 8
Totale 31.660
Nazione #
US - Stati Uniti d'America 18.064
GB - Regno Unito 3.024
CN - Cina 1.468
SG - Singapore 1.452
HK - Hong Kong 1.281
IT - Italia 1.130
SE - Svezia 941
DE - Germania 857
UA - Ucraina 543
BR - Brasile 514
TR - Turchia 467
RU - Federazione Russa 368
FI - Finlandia 334
BG - Bulgaria 207
FR - Francia 179
KR - Corea 89
IN - India 58
VN - Vietnam 53
NL - Olanda 42
BE - Belgio 30
ID - Indonesia 29
BD - Bangladesh 28
CA - Canada 28
AR - Argentina 25
ES - Italia 22
MX - Messico 22
MY - Malesia 21
CZ - Repubblica Ceca 18
IE - Irlanda 18
JP - Giappone 18
TW - Taiwan 17
LT - Lituania 16
IR - Iran 14
AT - Austria 13
IQ - Iraq 13
ZA - Sudafrica 12
AU - Australia 11
RO - Romania 11
CL - Cile 10
MA - Marocco 10
PL - Polonia 10
EC - Ecuador 9
CH - Svizzera 8
UZ - Uzbekistan 8
VE - Venezuela 8
EU - Europa 7
NZ - Nuova Zelanda 7
PE - Perù 6
PK - Pakistan 6
SI - Slovenia 6
ET - Etiopia 5
JO - Giordania 5
TN - Tunisia 5
AZ - Azerbaigian 4
BO - Bolivia 4
CO - Colombia 4
CR - Costa Rica 4
EG - Egitto 4
GE - Georgia 4
HU - Ungheria 4
JM - Giamaica 4
KE - Kenya 4
PH - Filippine 4
UG - Uganda 4
BY - Bielorussia 3
CY - Cipro 3
GR - Grecia 3
IL - Israele 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
NP - Nepal 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
DZ - Algeria 2
HN - Honduras 2
HR - Croazia 2
KW - Kuwait 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PY - Paraguay 2
QA - Qatar 2
TH - Thailandia 2
TJ - Tagikistan 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BF - Burkina Faso 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GT - Guatemala 1
KG - Kirghizistan 1
LV - Lettonia 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NG - Nigeria 1
PT - Portogallo 1
SA - Arabia Saudita 1
Totale 31.657
Città #
Fairfield 2.189
Southend 2.017
Santa Clara 1.914
Woodbridge 1.601
Hong Kong 1.276
Houston 1.276
Jacksonville 1.219
Ashburn 1.197
Chandler 1.197
Seattle 835
Singapore 824
Dearborn 796
Ann Arbor 776
Wilmington 762
Cambridge 720
Nyköping 546
London 499
Beijing 343
Modena 305
Hefei 303
Izmir 285
San Diego 235
Princeton 220
Sofia 207
Eugene 201
Des Moines 166
New York 150
Moscow 122
Helsinki 112
Shanghai 112
Grafing 101
Council Bluffs 87
Falls Church 86
Munich 79
Seoul 78
The Dalles 75
Bremen 58
Rome 57
Milan 55
Kunming 46
São Paulo 44
Boardman 42
Redwood City 39
Norwalk 35
San Mateo 33
Fremont 31
Guangzhou 31
Bologna 30
Brussels 27
Los Angeles 27
Jakarta 25
Turku 25
Kilburn 23
Chicago 22
San Francisco 20
Jinan 19
Nanjing 19
Verona 19
Bari 18
Hanoi 18
Ho Chi Minh City 18
Hounslow 18
Dongguan 17
Frankfurt am Main 17
Columbus 15
Dallas 15
Dublin 15
Parma 15
Rio de Janeiro 15
Brno 14
Chiswick 14
Nanchang 14
Toronto 14
Belo Horizonte 13
Phoenix 12
Fuzhou 11
Xi'an 11
Chongqing 10
Indiana 10
Istanbul 10
Nuremberg 10
Shenyang 10
Taipei 10
Washington 10
Wuhan 10
Amsterdam 9
Auburn Hills 9
Augusta 9
Florence 9
Madrid 9
Naples 9
North Salt Lake 9
Palermo 9
Sydney 9
Formia 8
Genova 8
Islington 8
Leawood 8
Mountain View 8
Saint Petersburg 8
Totale 24.131
Nome #
Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study 349
Herpesvirus DNA is frequently detected in liver tissue from hepatitis C patients 297
ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population 273
Suppression of bile acid synthesis, but not of hepatic cholesterol 7alpha-hydroxylase expression, by obstructive cholestasis in humans 265
Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes 264
Age-associated alterations in cholesterol homeostasis: evidence from a cross-sectional study in a Northern Italy population. 257
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 257
Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease 244
Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors 242
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity 239
Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: A possible compensatory mechanism. 237
Comparative cytotoxic and cytoprotective effects of taurohyodeoxycholic acid (THDCA) and tauroursodeoxycholic acid (TUDCA) in HepG2 cell line. 237
Gender, fatty liver and GGT 234
Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? 230
Il pool degli acidi biliari quale regolatore del metabolismo epatico del colesterolo: sintesi degli acidi biliari. 229
Nonalcoholic fatty liver disease and aging: epidemiology to management 226
Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. 223
Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis 222
Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease. 221
Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD) 218
Review article: the metabolic syndrome and non-alcoholic fatty liver disease 217
Magnetic resonance for quantitative assessment of liver steatosis: a new potential tool to monitor antiretroviral-drug-related toxicities. 215
In Vivo Degradation of Cholesterol to Bile Acids Is Reduced in Patients Receiving Parenteral Nutrition. 215
Risk for cardiovascular events in an Italian population of patients with type 2 diabetes 212
Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis. 211
Treatment of atherogenic liver based on the pathogenesis of nonalcoholic Fatty liver disease: a novel approach to reduce cardiovascular risk? 210
Risk factors for hospital readmission of elderly patients 208
Liver and kidney foreign bodies granulomatosis in a patient with malocclusion, bruxism, and worn dental prostheses 208
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. 207
Effect of liver cirrhosis on the systemic availability of naltrexone in humans 206
Review article: diabetes, genetics and ethnicity 203
Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen 203
Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD 202
Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. 195
Bile acid feeding and hepatic sterol metabolism: effect of deoxycholic acid. 195
Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the MICOL project) 194
Advances in the comprehension of the pathophysiology of bile secretion 193
Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia? 191
Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis 190
Multiecho MR sequences and high-resolution magic angle spinning (HRMAS)ex-vivo spectroscopy in the qualitative analysis and differentiationbetween steatohepatitis and steatosis 190
Endocrine and liver interaction: the role of endocrine pathways in NASH 190
Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans 189
Review article: hepatic steatosis and insulin resistance 189
Clinical physiology of NAFLD: A critical overview of pathogenesis and treatment 188
From NAFLD in clinical practice to answers from guidelines. 187
Chicken or egg turned into head or belly 186
Effect of the selective expansion of cholic acid pool on bile lipid composition: possible mechanism of bile acid induced biliary cholesterol desaturation. 186
Patogenesi della colelitiasi. I. Colelitiasi colesterinica. 186
Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. 185
Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: Prevalence and correlates 185
Cholesterol absorption in cirrhosis: the role of total and individual bile acid pool size 184
The hepatitis C virus-associated dysmetabolic syndrome. 184
Effects of acute changes of bile acid pool composition on biliary lipid secretion 183
Apolipoprotein synthesis in nonalcoholic steatohepatitis 183
Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7 alpha-hydroxylation rates in vivo. 182
Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question 182
Anatomia e fisiologia delle vie biliari 181
Is cholangiocarcinoma another complication of insulin resistance: A report of three cases 181
NAFLD AND TYPE 2 DIABETES: A GENETIC OR METABOLIC ISSUE? 181
'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis 180
Determinants of bile secretion: effect of bile salt structure on bile flow and biliary cation secretion 179
NAFLD and cardiovascular risk: direct evidence for the tale of two ages. 178
Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. 177
Intestinal solubilization, absorption, pharmacokinetics and bioavailability of chenodeoxycholic acid. 176
Statins and HCV: a complex issue 176
Relationship of serum fetuin-a levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography. 176
Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study 175
Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. 175
Growth hormone plasma levels in nonalcoholic fatty liver disease 174
Nonalcoholic fatty liver disease in HIV-infected persons: epidemiology and the role of nucleoside reverse transcriptase inhibitors. 174
Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease -Atherosclerosis As a Major Player in the Natural Course of NAFLD. 174
MR techniques in the qualitative analysis of liver steatosis: the potential in the differentiation between steatohepatatis and steatosis 173
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. 172
Bile acid structure and regulation of biliary protein secretion and composition in man 171
MOLECULAR REGULATION OF STEROL METABOLISM BY BILE ACIDS IN CULTURED HUMAN HEPATOCYTES 171
Of liver, whisky and plants: A requiem for colchicine in alcoholic cirrhosis? 171
Effect of ursocholic acid on bile lipid secretion and composition 170
Progetto MICOL - Multicentrica Italiana Colelitiasi 170
Non-alcoholic Fatty Liver Disease: a HR-MAS analysis 169
ESTIMATION OF CARDIOVASCULAR RISK IN TYPE 2 DIABETES 169
The effect of chenodeoxycholic acid (CDCA) on cholesterol absorption. 168
Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short erm feeding of chenodeoxycholic and ursodeoxycholic acid 168
'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? 168
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients 168
Fisiologia della secrezione biliare. 167
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. 166
Nonalcoholic fatty liver disease induced by leuprorelin acetate 166
Nuclear receptors as potential molecular targets in cholesterol accumulation conditions: Insights from evidence on hepatic cholesterol degradation and gallstone disease in humans 165
Effect of diabetic autonomic neuropathy on gallbladder kinetics in insulin dependent diabetic patients 164
Liver and diabetes. A vicious circle 164
Influence of age and sex on serum concentrations of total dimeric activin A 163
The prediction of coronary heart disease mortality as a function of major risk factors in over 30.000 men in the italian RIFLE Pooling Project. A comparison with the MRFIT primary screenees 163
Metabolic alterations and chronic hepatitis C: treatment strategies. 163
Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B. 163
Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: what do they mean and do they agree? 162
Diet and gallstones in Italy: the cross-sectional MICOL results. 161
Regolazione della sintesi di colesterolo e acidi biliari 161
Hepatitis C and diabetes: the inevitable coincidence? 160
RISK FOR CARDIOVASCULAR EVENTS IN AN ITALIAN POPULATION OF PATIENTS WITH TYPE 2 DIABETES 160
Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease 158
Totale 19.469
Categoria #
all - tutte 138.021
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 138.021


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020240 0 0 0 0 0 0 0 0 0 0 0 240
2020/20213.733 363 139 324 320 391 294 369 545 133 452 257 146
2021/20223.583 51 502 394 313 87 156 261 204 392 213 607 403
2022/20233.279 363 354 205 326 401 583 72 310 385 29 142 109
2023/20242.003 84 119 114 136 457 221 216 286 56 42 75 197
2024/20257.395 263 87 129 495 1.607 971 588 413 707 257 838 1.040
Totale 31.812